Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Qure Biotechnology (Shanghai) Co. Ltd. operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently associated with this portfolio. These actions are distributed across 2 distinct art units, suggesting that the pending matters cover different technical aspects of biotechnology. The prosecution involves 2 distinct examiners. This distribution shows that the company's current patent applications are being reviewed by multiple individuals across different specialized units.
HOPKINS, SAMANTHA LAKE is the busiest examiner for Qure Biotechnology (Shanghai) Co. Ltd. This examiner is currently responsible for 1 pending office action. With a total of 2 pending office actions, the workload is divided between the 2 distinct examiners. This means that HOPKINS, SAMANTHA LAKE is managing 1 of the company's current pending office actions. This distribution shows that no single examiner is managing more than 1 of the company's current pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| LU, CHENG | 1 | 53.8% | +64.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | — |
| 18256023 | TRIFUNCTIONAL FUSION PROTEIN CONTAINING TUMOR-ASSOCIATED ANTIGEN (TAA) ANTIBODY AND APPLICATION THEREOF | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566817 | ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION | HOPKINS, SAMANTHA LAKE | 1641 | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18256023 | TRIFUNCTIONAL FUSION PROTEIN CONTAINING TUMOR-ASSOCIATED ANTIGEN (TAA) ANTIBODY AND APPLICATION THEREOF | LU, CHENG | 1642 | §103 | Final Rejection | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQure Biotechnology (Shanghai) Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Samantha Lake Hopkins has the most, with 1 of Qure Biotechnology (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
